XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Statements of Operations-Additional Information | 12 Months Ended
--- | ---
Jun. 30, 2022
Statements of Operations-Additional Information |
Disaggregated Revenue, Deferred Revenue and Customer Payment Terms | Disaggregated revenue, deferred revenue and customer payment terms We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. The products help prevent, control and treat diseases, enhance nutrition to help improve animal health and well-being, and contribute to balanced mineral nutrition. The animal health and mineral nutrition products are sold directly to integrated poultry, swine and cattle integrators and through animal feed manufacturers, wholesalers and distributors. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused in regions where the majority of livestock production is consolidated in large commercial farms. We have a diversified portfolio of products that are classified within our three business segments — Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team. Animal Health The Animal Health business develops, manufactures and markets products in three main categories:
| ● | MFAs and Other: MFAs and other products primarily consist of concentrated medicated products that are administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products.
| ● | Nutritional Specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers.
| ● | Vaccines: Our vaccines are primarily focused on preventing diseases in poultry and swine. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products and produce and market adjuvants to vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.
Mineral Nutrition The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their animals’ diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine and beef and dairy cattle. Performance Products The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States. The following tables present our revenues disaggregated by major product category and geographic region: Net Sales by Product Type ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30 | ​ | 2022 | ​ | 2021 | ​ | 2020
Animal Health | ​ | ​ |  |  | ​ |  | ​ | ​ | ​
MFAs and other | ​ | $ | 361,538 | ​ | $ | 330,017 | ​ | $ | 322,300
Nutritional specialties | ​ |  | 157,196 | ​ |  | 142,760 | ​ | ​ | 129,264
Vaccines | ​ |  | 88,321 | ​ |  | 72,939 | ​ | ​ | 75,340
Total Animal Health | ​ | $ | 607,055 | ​ | $ | 545,716 | ​ | $ | 526,904
Mineral Nutrition | ​ |  | 259,512 | ​ |  | 220,560 | ​ | ​ | 214,412
Performance Products | ​ |  | 75,694 | ​ |  | 67,074 | ​ | ​ | 59,038
Total | ​ | $ | 942,261 | ​ | $ | 833,350 | ​ | $ | 800,354
​ Net Sales by Region ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30 | ​ | 2022 |  | 2021 |  | 2020
United States | ​ | $ | 561,803 | ​ | $ | 494,889 | ​ | $ | 471,938
Latin America and Canada | ​ |  | 191,047 | ​ |  | 166,325 | ​ | ​ | 158,939
Europe, Middle East and Africa | ​ |  | 122,480 | ​ |  | 114,131 | ​ | ​ | 112,179
Asia Pacific | ​ |  | 66,931 | ​ |  | 58,005 | ​ | ​ | 57,298
Total | ​ | $ | 942,261 | ​ | $ | 833,350 | ​ | $ | 800,354
​ ​ Net sales by region are based on country of destination. Deferred revenue was $2,051 and $3,674 as of June 30, 2022 and June 30, 2021, respectively. Accrued expenses and other current liabilities included $822 and $1,560 of the total deferred revenue as of June 30, 2022 and 2021, respectively. The deferred revenue resulted primarily from certain customer arrangements, including technology licensing fees and discounts on future product sales. The transaction price associated with our deferred revenue arrangements is generally based on the stand-alone sales prices of the individual products or services. Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized.
Additional Information | Additional Information ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30 | ​ | 2022 |  | 2021 |  | 2020
Interest expense, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Term loan | ​ | $ | 8,962 | ​ | $ | 7,951 | ​ | $ | 7,751
Revolving credit facility | ​ |  | 2,956 | ​ |  | 3,649 | ​ |  | 5,317
Amortization of debt issuance costs | ​ |  | 590 | ​ |  | 833 | ​ |  | 882
Refinancing expense | ​ | ​ | — | ​ | ​ | 1,020 | ​ | ​ | —
Other | ​ |  | 183 | ​ |  | 265 | ​ |  | 663
Interest expense | ​ |  | 12,691 | ​ |  | 13,718 | ​ |  | 14,613
Interest income | ​ |  | (816) | ​ |  | (838) | ​ |  | (1,757)
​ | ​ | $ | 11,875 | ​ | $ | 12,880 | ​ | $ | 12,856
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ ​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30 |  | 2022 |  | 2021 |  | 2020
Depreciation and amortization | ​ |  | ​ | ​ |  | ​ | ​ |  |
Depreciation of property, plant and equipment | ​ | $ | 23,781 | ​ | $ | 23,165 | ​ | $ | 23,250
Amortization of intangible assets | ​ |  | 8,924 | ​ |  | 8,715 | ​ |  | 8,869
Amortization of other assets | ​ |  | — | ​ |  | 5 | ​ |  | 222
​ | ​ | $ | 32,705 | ​ | $ | 31,885 | ​ | $ | 32,341
​ ​ Depreciation of property, plant and equipment includes amortization of capitalized software costs of $1,047, $1,254 and $1,038 during 2022, 2021 and 2020, respectively. Future amortization of intangible assets as of June 30, 2022, is expected to be: ​
​ | ​ | ​ | ​
For the Year Ended June 30 |  | ​ |
2023 | ​ | $ | 9,614
2024 | ​ |  | 9,375
2025 | ​ |  | 7,769
2026 | ​ |  | 6,805
2027 | ​ |  | 6,556
Thereafter | ​ |  | 23,742
Total | ​ | $ | 63,861
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
For the Year Ended June 30 |  | 2022 |  | 2021 |  | 2020
Research and development expense | ​ | $ | 20,832 | ​ | $ | 17,759 | ​ | $ | 13,738
​

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_IncomeStatementRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI https://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration